PVT1 and prostate carcinoma: To identify the underlying molecular mechanism of PVT1 activity in GBC cells, bioinformatics analysis revealed that miR-143, which had been previously demonstrated to be a tumor suppressor in several types of cancers, including GBC, prostate cancer and pancreatic cancer [31–33], might have potential PVT1 binding sites.